OBJECTIVE: To describe and compare differences in the epidemiologic, clinical, and laboratory characteristics of pregnant women with confirmed or probable Zika virus infection and to compare the risk of having a neonate with laboratory evidence of Zika virus infection with that of having a neonate without evidence of Zika virus infection by maternal characteristics. METHODS: We conducted a retrospective cohort study of women with Zika virus infection who completed pregnancy in New York City from January 1, 2016 to June 30, 2017. Confirmed Zika virus infection was defined as 1) nucleic acid amplification test-detected Zika virus, or 2) a nonnegative enzyme-linked immunosorbent assay test result and a plaque-reduction neutralization test result positive for Zika virus but negative for dengue virus, or 3) delivery of a neonate with laboratory evidence of Zika virus infection. Probable infection was defined as a nonnegative enzyme-linked immunosorbent assay test result and a positive plaque-reduction neutralization test result for Zika virus and dengue virus. RESULTS: We identified 390 women with confirmed (28%) or probable (72%) Zika virus infection. Fever, rash, arthralgia, or conjunctivitis was reported by 31% of women and were more common among women with confirmed than with probable infection (43% vs 26%, P=.001). Of 366 neonates born to these women, 295 (81%) were tested for Zika virus and 22 (7%) had laboratory-diagnosed congenital Zika virus infection. The relative risk (RR) for having a neonate with laboratory evidence of Zika virus infection was greater among women with fever (RR 4.8, 95% CI 2.1-10.7), tingling (RR 4.8, CI 1.7-13.7), or numbness (RR 6.9, CI 2.6-18.2) during pregnancy or the periconception period. However, the RR did not differ whether the mother had confirmed or probable Zika virus infection (RR 1.6, CI 0.7-4.1). CONCLUSION: In New York City, a greater proportion of women had probable Zika virus infection than confirmed infection. Women with some symptoms during pregnancy or periconceptionally were more likely to have a neonate with laboratory evidence of Zika virus infection. Neonates born to women with confirmed or probable Zika virus infection should be tested for Zika virus infection.
OBJECTIVE: To describe and compare differences in the epidemiologic, clinical, and laboratory characteristics of pregnant women with confirmed or probable Zika virus infection and to compare the risk of having a neonate with laboratory evidence of Zika virus infection with that of having a neonate without evidence of Zika virus infection by maternal characteristics. METHODS: We conducted a retrospective cohort study of women with Zika virus infection who completed pregnancy in New York City from January 1, 2016 to June 30, 2017. Confirmed Zika virus infection was defined as 1) nucleic acid amplification test-detected Zika virus, or 2) a nonnegative enzyme-linked immunosorbent assay test result and a plaque-reduction neutralization test result positive for Zika virus but negative for dengue virus, or 3) delivery of a neonate with laboratory evidence of Zika virus infection. Probable infection was defined as a nonnegative enzyme-linked immunosorbent assay test result and a positive plaque-reduction neutralization test result for Zika virus and dengue virus. RESULTS: We identified 390 women with confirmed (28%) or probable (72%) Zika virus infection. Fever, rash, arthralgia, or conjunctivitis was reported by 31% of women and were more common among women with confirmed than with probable infection (43% vs 26%, P=.001). Of 366 neonates born to these women, 295 (81%) were tested for Zika virus and 22 (7%) had laboratory-diagnosed congenital Zika virus infection. The relative risk (RR) for having a neonate with laboratory evidence of Zika virus infection was greater among women with fever (RR 4.8, 95% CI 2.1-10.7), tingling (RR 4.8, CI 1.7-13.7), or numbness (RR 6.9, CI 2.6-18.2) during pregnancy or the periconception period. However, the RR did not differ whether the mother had confirmed or probable Zika virus infection (RR 1.6, CI 0.7-4.1). CONCLUSION: In New York City, a greater proportion of women had probable Zika virus infection than confirmed infection. Women with some symptoms during pregnancy or periconceptionally were more likely to have a neonate with laboratory evidence of Zika virus infection. Neonates born to women with confirmed or probable Zika virus infection should be tested for Zika virus infection.
Authors: Hannah J Cooper; Martha Iwamoto; Maura Lash; Erin E Conners; Marc Paladini; Sally Slavinski; Anne D Fine; Joseph Kennedy; Dominique Heinke; Andrea Ciaranello; George R Seage; Ellen H Lee Journal: Obstet Gynecol Date: 2019-12 Impact factor: 7.661
Authors: A E Ades; Antoni Soriano-Arandes; Ana Alarcon; Francesco Bonfante; Claire Thorne; Catherine S Peckham; Carlo Giaquinto Journal: Lancet Infect Dis Date: 2020-10-14 Impact factor: 25.071
Authors: A E Ades; Elizabeth B Brickley; Neal Alexander; David Brown; Thomas Jaenisch; Demócrito de Barros Miranda-Filho; Moritz Pohl; Kerstin D Rosenberger; Antoni Soriano-Arandes; Claire Thorne; Ricardo Arraes de Alencar Ximenes; Thalia Velho Barreto de Araújo; Vivian I Avelino-Silva; Sarah Esperanza Bethencourt Castillo; Victor Hugo Borja Aburto; Patrícia Brasil; Celia D C Christie; Wayner Vieira de Souza; Jose Eduardo Gotuzzo H; Bruno Hoen; Marion Koopmans; Celina Maria Turchi Martelli; Mauro Martins Teixeira; Ernesto T A Marques; Maria Consuelo Miranda; Ulisses Ramos Montarroyos; Maria Elisabeth Moreira; J Glenn Morris; Barry Rockx; Paola Mariela Saba Villarroel; Carmen Soria Segarra; Adriana Tami; Marília Dalva Turchi; Carlo Giaquinto; Xavier de Lamballerie; Annelies Wilder-Smith Journal: BMJ Open Date: 2020-12-15 Impact factor: 2.692
Authors: Antoni Soriano-Arandes; Marie Antoinette Frick; Milagros García López-Hortelano; Elena Sulleiro; Carlota Rodó; María Paz Sánchez-Seco; Marta Cabrera-Lafuente; Anna Suy; María De la Calle; Mar Santos; Eugenia Antolin; María Del Carmen Viñuela; María Espiau; Ainara Salazar; Borja Guarch-Ibáñez; Ana Vázquez; Juan Navarro-Morón; José-Tomás Ramos-Amador; Andrea Martin-Nalda; Eva Dueñas; Daniel Blázquez-Gamero; Resurrección Reques-Cosme; Iciar Olabarrieta; Luis Prieto; Fernando De Ory; Claire Thorne; Thomas Byrne; Anthony E Ades; Elisa Ruiz-Burga; Carlo Giaquinto; María José Mellado-Peña; Alfredo García-Alix; Elena Carreras; Pere Soler-Palacín Journal: Pathogens Date: 2020-05-07